Embecta Corp. EMBC
Institutional shares held
52.4 Million
120K
calls
66.8K
puts
Total value of holdings
$658M
$1.51M
calls
$839K
puts
Market Cap
$726M
57,836,500
Shares Out.
Institutional ownership
90.61%
# of Institutions
399
We take great care to ensure that the data presented and summarized in this overview for Embecta Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EMBC
View all-
Black Rock Inc. New York, NY9.19MShares$115 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.03MShares$88.2 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.27MShares$41.1 Million1.68% of portfolio
-
American Century Companies Inc Kansas City, MO3.26MShares$41 Million0.04% of portfolio
-
River Road Asset Management, LLC3.25MShares$40.8 Million0.95% of portfolio
-
State Street Corp Boston, MA2.37MShares$29.7 Million0.0% of portfolio
-
Donald Yacktman Yacktman Asset Management LP2.36MShares$29.6 Million0.43% of portfolio
-
Geode Capital Management, LLC Boston, MA1.38MShares$17.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$14.2 Million0.01% of portfolio
-
Rubric Capital Management LP New York, NY1.09MShares$13.6 Million0.37% of portfolio
Latest Institutional Activity in EMBC
Top Purchases
Top Sells
About EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Insider Transactions at EMBC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 04
2025
|
Jacob Elguicze SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,948
-2.85%
|
$59,376
$12.0 P/Share
|
|
Apr 04
2025
|
Jeffrey Z Mann SVP, GC, Head Corp. Dev., Secy |
SELL
Payment of exercise price or tax liability
|
Direct |
5,285
-3.65%
|
$63,420
$12.0 P/Share
|
|
Apr 04
2025
|
Shaun Curtis SVP, Global Manuf./Sup. Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
3,249
-5.21%
|
$38,988
$12.0 P/Share
|
|
Apr 04
2025
|
Devdatt Kurdikar President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
39,592
-7.34%
|
$475,104
$12.0 P/Share
|
|
Feb 25
2025
|
David F Melcher Director |
BUY
Open market or private purchase
|
Direct |
13,000
+14.5%
|
$169,000
$13.67 P/Share
|
|
Feb 13
2025
|
Milton Mayo Morris Director |
SELL
Open market or private sale
|
Direct |
3,100
-7.9%
|
$49,600
$16.38 P/Share
|
|
Feb 12
2025
|
Milton Mayo Morris Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+26.08%
|
-
|
|
Feb 12
2025
|
David Albritton Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+25.83%
|
-
|
|
Feb 12
2025
|
Carrie L Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+25.83%
|
-
|
|
Feb 12
2025
|
Karen Prange Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+25.83%
|
-
|
|
Feb 12
2025
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+23.41%
|
-
|
|
Feb 12
2025
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+25.82%
|
-
|
|
Feb 12
2025
|
Claire Pomeroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+25.1%
|
-
|
|
Feb 12
2025
|
David F Melcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,450
+21.51%
|
-
|
|
Dec 02
2024
|
Anthony M. Roth Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,762
+50.0%
|
-
|
|
Nov 26
2024
|
Jacob Elguicze SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,785
-5.42%
|
$176,130
$18.7 P/Share
|
|
Nov 26
2024
|
Jacob Elguicze SVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
61,498
+25.4%
|
-
|
|
Nov 26
2024
|
Shaun Curtis SVP, Global Manuf./Sup. Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
5,806
-8.64%
|
$104,508
$18.7 P/Share
|
|
Nov 26
2024
|
Shaun Curtis SVP, Global Manuf./Sup. Chain |
BUY
Grant, award, or other acquisition
|
Direct |
24,065
+26.37%
|
-
|
|
Nov 26
2024
|
Devdatt Kurdikar President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
48,956
-8.44%
|
$881,208
$18.7 P/Share
|
Last 12 Months Summary
Buy / Acquisition
490K
Shares
From
15
Insiders
| Grant, award, or other acquisition | 477K shares |
|---|---|
| Open market or private purchase | 13K shares |
Sell / Disposition
132K
Shares
From
6
Insiders
| Open market or private sale | 3.1K shares |
|---|---|
| Payment of exercise price or tax liability | 129K shares |